Biosimilars & Biologics 2017

DESCRIPTION

The BioTech Pharma Summit – Biosimilars & Biologics 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.

Over 100 delegates working in biosimilars and biologics, proteins, antibodies and peptides, representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Global summit in Porto, reserve your seat now at the Biosimilars & Biologics 2017!

KEY PRACTICAL LEARNING POINTS

  • Biosimilars Interchangeability
  • Biosimilar Orphan Drugs: The Next Regulatory Challenge
  • The latest trends of the Biosimilars & Biologics
  • Prognosis for the Global Biologics market in an era of transformative new technologies
  • Innovative products and technologies in the global biologics market
  • Sustainable biotech innovation and the emergence of biosimilars
  • Obtaining patent protection while operating in an “anti-patent” climate From biosimilar approval to biogenerics in clinical practice
  • Biosimilars in emerging markets – regulatory and commercial considerations
  • Establishing “Finger-print Like” Biosimilarity – Critical Characterization Strategies for Biosimilar Assessment

WHO SHOULD ATTEND?

The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Biologics/Biotechnology/ Biogenerics
  • Biopharmaceuticals
  • Business Development
  • Chief Scientific Officer
  • Clinical Immunology
  • Commercial Affairs
  • Drug and Safety Assessment
  • Drug Safety & Risk Management
  • Intellectual property
  • Legislation and Policy Advice
  • Manufacturing Market
  • Strategy Marketing & sales
  • New Product Development
  • Pharmacovigilance
  • Preclinical and Clinical Development
  • Pricing and Reimbursement
  • Health Economics
  • Principal Scientist
  • Process Control and Analytical Technologies
  • Quality Affairs/ Quality Control
  • Regulatory Affairs
  • Regulatory Compliance
  • Legal Affairs
  • R & D
Edward Abrahams
President at Personalized Medicine Coalition (PMC)
Steinar Madsen
Medical Director
Cecil Nick
Vice President
Helder Mota Filipe
Former Vice-President
Rodeina Challand
Director
Joanna Brougher
Owner & Principal
Dairine Dempsey
Dairine Dempsey
CEO & co-founder at Open Orphan DAC
Uwe Gudat
Uwe Gudat
Head of Safety, Biosimilars
Fiona Greer
Life Sciences Global Director, Biopharma Services Development
Paul Song
Vice President
Arnout Ploos van Amstel
Head of Global Business Franchise Immunology & Dermatology (I&D)
James Smith
Programme Coordinator and Research Associate
Sarah Rickwood
Vice President, Thought Leadership
Javier Camposano
Head of the Drug Product Division
António Pregueiro
Vice President Life Sciences Europe
Samir Kulkarni
Associate Vice President, Product Development and Strategic Program Management
Shane Maloney
Transaction Director
David Brindley
Managing Partner
Abhishek Kulshrestha
Principal Scientific manager
Event Details
Sponsors